Your browser doesn't support javascript.
loading
Macrovascular Networks on Contrast-Enhanced Magnetic Resonance Imaging Improves Survival Prediction in Newly Diagnosed Glioblastoma.
Puig, Josep; Biarnés, Carles; Daunis-I-Estadella, Pepus; Blasco, Gerard; Gimeno, Alfredo; Essig, Marco; Balaña, Carme; Alberich-Bayarri, Angel; Jimenez-Pastor, Ana; Camacho, Eduardo; Thio-Henestrosa, Santiago; Capellades, Jaume; Sanchez-Gonzalez, Javier; Navas-Martí, Marian; Domenech-Ximenos, Blanca; Del Barco, Sonia; Puigdemont, Montserrat; Leiva-Salinas, Carlos; Wintermark, Max; Nael, Kambiz; Jain, Rajan; Pedraza, Salvador.
Afiliación
  • Puig J; Department of Radiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada. jpuig@hsc.mb.ca.
  • Biarnés C; Research Unit of Diagnostic Imaging Institute (IDI), Department of Radiology (Girona Biomedical Research Institute) IDIBGI, Hospital Universitari Dr Josep Trueta, 17007 Girona, Spain. jpuig@hsc.mb.ca.
  • Daunis-I-Estadella P; Research Unit of Diagnostic Imaging Institute (IDI), Department of Radiology (Girona Biomedical Research Institute) IDIBGI, Hospital Universitari Dr Josep Trueta, 17007 Girona, Spain. carlesbiarnes90@gmail.com.
  • Blasco G; Department of Computer Science, Applied Mathematics and Statistics, University of Girona, 17003 Girona, Spain. pepus@imae.udg.edu.
  • Gimeno A; Research Unit of Diagnostic Imaging Institute (IDI), Department of Radiology (Girona Biomedical Research Institute) IDIBGI, Hospital Universitari Dr Josep Trueta, 17007 Girona, Spain. gbs.blasco@gmail.com.
  • Essig M; Research Unit of Diagnostic Imaging Institute (IDI), Department of Radiology (Girona Biomedical Research Institute) IDIBGI, Hospital Universitari Dr Josep Trueta, 17007 Girona, Spain. fredigimeno1989@gmail.com.
  • Balaña C; Department of Radiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada. messig@exchange.hsc.mb.ca.
  • Alberich-Bayarri A; Medical Oncology, Institut Catala Oncologia (ICO), Applied Research Group in Oncology (B-ARGO), IGTP, Badalona, 08916 Barcelona, Spain. cbalana@iconcologia.net.
  • Jimenez-Pastor A; QUIBIM SL, Quantitative Imaging Biomarkers in Medicine, 46026 Valencia, Spain. angel@quibim.com.
  • Camacho E; QUIBIM SL, Quantitative Imaging Biomarkers in Medicine, 46026 Valencia, Spain. anajimenez@quibim.com.
  • Thio-Henestrosa S; QUIBIM SL, Quantitative Imaging Biomarkers in Medicine, 46026 Valencia, Spain. educamacho@quibim.com.
  • Capellades J; Department of Computer Science, Applied Mathematics and Statistics, University of Girona, 17003 Girona, Spain. santiago.thio@udg.edu.
  • Sanchez-Gonzalez J; Department of Radiology, Hospital del Mar, 08003 Barcelona, Spain. jaumecapellades@gmail.com.
  • Navas-Martí M; Philips Healthcare Ibérica, 28050 Madrid, Spain. javier.sanchez.gonzalez@philips.com.
  • Domenech-Ximenos B; Research Unit of Diagnostic Imaging Institute (IDI), Department of Radiology (Girona Biomedical Research Institute) IDIBGI, Hospital Universitari Dr Josep Trueta, 17007 Girona, Spain. marianmarti33@gmail.com.
  • Del Barco S; Research Unit of Diagnostic Imaging Institute (IDI), Department of Radiology (Girona Biomedical Research Institute) IDIBGI, Hospital Universitari Dr Josep Trueta, 17007 Girona, Spain. bl.domenech@gmail.com.
  • Puigdemont M; Medical Oncology, Institut Catala Oncologia (ICO), 17007 Girona, Spain. Sdelbarco@iconcologia.net.
  • Leiva-Salinas C; Hospital Cancer Registry, ICO, Hospital Universitari Dr Josep Trueta, 17007 Girona, Spain. mpuigdemont@iconcologia.net.
  • Wintermark M; Department of Radiology, University of Missouri, Columbia, MO 65212, USA. carlosleivasalinas@gmail.com.
  • Nael K; Department of Radiology, Neuroradiology Division, Stanford University, Stanford, CA 94304, USA. mwinterm@stanford.edu.
  • Jain R; Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. kambiznael@gmail.com.
  • Pedraza S; Departments of Radiology and Neurosurgery, New York University School of Medicine, New York, NY 10016, USA. Rajan.Jain@nyumc.org.
Cancers (Basel) ; 11(1)2019 Jan 14.
Article en En | MEDLINE | ID: mdl-30646519
ABSTRACT
A higher degree of angiogenesis is associated with shortened survival in glioblastoma. Feasible morphometric parameters for analyzing vascular networks in brain tumors in clinical practice are lacking. We investigated whether the macrovascular network classified by the number of vessel-like structures (nVS) visible on three-dimensional T1-weighted contrast⁻enhanced (3D-T1CE) magnetic resonance imaging (MRI) could improve survival prediction models for newly diagnosed glioblastoma based on clinical and other imaging features. Ninety-seven consecutive patients (62 men; mean age, 58 ± 15 years) with histologically proven glioblastoma underwent 1.5T-MRI, including anatomical, diffusion-weighted, dynamic susceptibility contrast perfusion, and 3D-T1CE sequences after 0.1 mmol/kg gadobutrol. We assessed nVS related to the tumor on 1-mm isovoxel 3D-T1CE images, and relative cerebral blood volume, relative cerebral flow volume (rCBF), delay mean time, and apparent diffusion coefficient in volumes of interest for contrast-enhancing lesion (CEL), non-CEL, and contralateral normal-appearing white matter. We also assessed Visually Accessible Rembrandt Images scoring system features. We used ROC curves to determine the cutoff for nVS and univariate and multivariate cox proportional hazards regression for overall survival. Prognostic factors were evaluated by Kaplan-Meier survival and ROC analyses. Lesions with nVS > 5 were classified as having highly developed macrovascular network; 58 (60.4%) tumors had highly developed macrovascular network. Patients with highly developed macrovascular network were older, had higher volumeCEL, increased rCBFCEL, and poor survival; nVS correlated negatively with survival (r = -0.286; p = 0.008). On multivariate analysis, standard treatment, age at diagnosis, and macrovascular network best predicted survival at 1 year (AUC 0.901, 83.3% sensitivity, 93.3% specificity, 96.2% PPV, 73.7% NPV). Contrast-enhanced MRI macrovascular network improves survival prediction in newly diagnosed glioblastoma.
Palabras clave

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2019 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Año: 2019 Tipo del documento: Article País de afiliación: Canadá